Supporting table 1 Pharmacological properties of DOR-eGFP expressed in HEK293 cells

	DOR	*n*	DOR-eGFP	*n*	p
Opioid ligands affinities: K_i (nM) [a]					
Met-enkephalin	9.5 ± 0.4	3	9.6 ± 1.6	3	0.95
β-endorphin	6.4 ± 1.2	3	5.3 ± 0.9	3	0.52
Deltorphin II	7.8 ± 0.7	3	7.6 ± 0.6	3	0.84
DPDPE	11.6 ± 0.4	3	10.3 ± 1.1	3	0.37
SNC80	2.8 ± 1.6	3	2.9 ± 1.0	3	0.96
[^{3}H]-diprenorphin (K_D)	1.3 ± 0.1	5	0.9 ± 0.1	5	0.07
Naltrindole	0.2 ± 0.1	3	0.2 ± 0.1	4	0.54
Deltorphin II-induced G protein activation[b]					
EC_{50} (nM)	1.5 ± 0.4	3	1.1 ± 0.5	3	0.57
Emax (% basal)	256 ± 11	3	223 ± 23	3	0.27
Deltorphin II-induced receptor down-regulation[c]					
Bmax (% basal)	7.1 ± 1.2	3	12.2 ± 4.8	3	0.40

[a] Binding affinities were measured in competition experiments using [^{3}H]-diprenorphin as the radioligand. [b] Activation of G proteins was quantified using the [^{35}S]-GTPγS binding assay. Deltorphin II potency (EC_{50}) and efficacy (Emax) are shown. [c] For receptor down-regulation experiments, cells were treated with 1 μM of deltorphin II for 24 hours. The number of receptor (Bmax) was measured in treated and untreated cells (basal). Reported values are mean ± sem. n indicates the number of independent experiments performed. Student t-test was used to determine p values.